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Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and is increasingly detected at small size
(<5cm) owing to surveillance programmes in high-risk patients. For these cases, curative therapies such as resection, liver trans-
plantation, or percutaneous ablation have been proposed. When surgical options are precluded, image-guided tumor ablation is
recommended as the most appropriate therapeutic choice in terms of tumor local control, safety, and improvement in survival.
Laser ablation (LA) represents one of currently available loco-ablative techniques: light is delivered via ﬂexible quartz ﬁbers of dia-
meter from 300 to 600μm inserted into tumor lesion through either ﬁne needles (21g Chiba needles) or large-bore catheters. The
thermal destruction of tissue is achieved through conversion of absorbed light (usually infrared) into heat. A range of diﬀerent
imagingmodalities have been used to guide percutaneous laser ablation, but ultrasound and magnetic resonance imagingare most
widelyemployed, accordingtolocal experienceandresourceavailability. Availableclinical datasuggestthatLAishighlyeﬀectivein
terms of tumoricidal capability with an excellent safety proﬁle; the best results in terms of long-term survival are obtained in early
HCC so that LA can be proposed not only in unresectable cases but, not diﬀerently from radiofrequency ablation, also as the ﬁrst-
line treatment.
1.Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
malignancy worldwide and the third leading cause of cancer-
related death [1]. Its incidence is continually rising mostly
as a result of the spread of hepatitis C virus infection [2–
4]. Patients with chronic hepatitis B or C virus infection are
at high risk of developing HCC. The annual incidence of
HCC in hepatitis B virus infection carriers is approximately
0.5–1% and reaches 2.5% in the presence of liver cirrhosis
[5, 6]. The incidence of HCC in chronic hepatitis C-related
liver cirrhosis is up to 2–8% [6–8]. With surveillance of the
high-risk population by ultrasonography and α-fetoprotein
(AFP), HCC is increasingly detected at small size, that is,
5cm or smaller in diameter [9–11]. However, a careful mul-
tidisciplinary assessment of tumor characteristics, liver func-
tion, and physical status is required for proper therapeutic
management even in patients with early-stage tumors [12].
Approximately, 30% to 40% of all HCC patients have early
tumors which can be treated with curative therapies such
as resection, liver transplantation, or percutaneous ablation
[12]. While surgical resection provides favourable long-term
survival [13, 14], only a minority of patients are suitable
for resection owing to multiple tumor nodules, concomitant
decompensated liver cirrhosis, lesion location, and/or severe
portal hypertension. Similarly, surgical resection carries a
signiﬁcant associated morbidity and mortality as well as a
disease recurrence rate of up to 75% [15, 16]. Liver trans-
plantation is more indicated in small HCC associated with
severe cirrhosis and oﬀers a satisfactory long-term outcome
[16–18], but the shortage of donor organs signiﬁcantly limits
its application. When surgical options are precluded, image-
guided tumor ablation is recommended as the most appro-
priate therapeutic choice and is considered a potentially
radical treatment in properly selected candidates [12]. This
technique is also cost eﬀective in comparison to other treat-
ments and is able to maximize the preservation of surround-
ing liver parenchyma whilst reducing in-patient hospitaliza-
tionrates[12,19,20].However,whetherornotpercutaneous
ablation can compete with surgery as the ﬁrst-line treatment2 Radiology Research and Practice
remains highly controversial and subject of debate. Laser
ablation (LA) represents one of a range of currently available
loco-ablative techniques with the majority of reported data
coming from Italy, Germany, and the UK [21].
2. GeneralPrinciplesand Techniques
2.1. Image-Guided Tumor Ablation. The term “image-guided
tumor ablation” is deﬁned as the direct application of chem-
ical or thermal therapies to a speciﬁc focal tumor(s) in an
attempt to achieve eradication or substantial tumor destruc-
tion [22]. Over the past 25 years, several methods for che-
micalorthermaltumordestructionhavebeendevelopedand
clinically tested [23], and image guidance is critical to the
success of these therapies [21, 24]. Although tumor ablation
procedurescanbeperformedatlaparoscopyorsurgery,most
procedures treating focal lesions are performed with percu-
taneous approach, explaining why these procedures are often
referred to as “percutaneous therapies.”
Thermal energy sources such as laser, radiofrequency
(RF), or microwave (MW) make the destruction of tumors
possible without surgical removal. The potential advantages
of in situ tumor ablation include decreased costs, reduced
morbidity, the possibility of performing procedures on out-
patients, and the possibility of treating patients who are poor
candidates for surgery due to age, comorbidity, or extent of
disease. The thermal ablation therapies involved in clinical
practice can be classiﬁed as either hyperthermic treatments,
including RF ablation (RFA), laser ablation (LA), MW abla-
tion (MWA), and high-intensity focused ultrasound (HI-
FU) or cryoablation (CA). The thermal damage caused by
heating depends on both the tissue temperature reached and
on the duration of heating. On the other hand, freezing tis-
s u ea tt e m p e r a t u r e sb e t w e e n−20◦Ca n d−60◦C, followed by
rapid thawing, results in cell membrane disruption and in-
duces cell death. In order to adequately destroy tumor tissue,
the entire target volume must be subjected to cytotoxic tem-
peratures [25].
2.2. Laser Ablation. The term “laser ablation” refers to the
thermal destruction of tissue by conversion of absorbed light
(usually infrared) into heat and includes various technical
variations on this theme including “interstitial photocoag-
ulation”, “laser coagulation therapy”, “laser interstitial tumor
therapy”,and“laser-inducedthermaltherapy”[26–34].Neo-
dymiun:yttrium aluminum garnet (Nd:YAG) lasers with a
wavelength of 1064nm are usually used for percutaneous LA
because penetration of light is optimal in the near infrared
spectrum [35]. In recent years, diode lasers with suitable
wavelengths have also been used [36]. Laser light penetra-
tes directly for a distance of between 12–15mm as a result of
backward and forward scattering and reﬂection and absorp-
tion. Scattering results in a relatively uniform distribution
of absorbed energy, and heat is produced by conversion of
absorbed light. Further away from the point of application,
the tissue is heated by conduction creating large coagulative
zones [27, 29, 30]. Temperature above 60◦C results in a ra-
pid coagulation zone and instant cell death. Irreversible cell
death, without preceding coagulation, occurs also at lower
hyperthermic temperatures (>42◦C) but requires durations
of treatment that vary negatively with temperature [29, 30,
37, 38]. Thus, it has been shown that LA at 46◦Cr e q u i -
res treatment for 30 minutes to ensure radicality [29, 39].
Temperatures above 100◦C will cause vaporization from eva-
poration of tissue water, and above 300◦C, tissue carboniza-
tion occurs. Overheating is thus best avoided as carboniza-
tion decreases optical penetration and heat conduction and
limits the size of lesions produced [33].
Ahighopticalpenetrationdepthreducesthetemperature
gradientbetweenthelaserﬁberandtissueandlessenstherisk
of overheating which prevents carbonization and vaporiza-
tion of tissue [33].Theoptical penetrationdepth isgreaterin
metastatic tissue than in normal liver, being 4.2 and 3.0mm,
respectively, at the 1064 wavelength. Coagulation necrosis
reduces optical penetration by about 20% in both normal
and tumor tissue [33, 40].
Using a bare tip, almost spherical lesions with a maxi-
mum diameter of 12–16mm can be produced [21]. Lesion
sizecanbeincreasedbyusingbeamsplittersforsimultaneous
use of multiple ﬁbers in an array around the tumor [32, 41].
This avoids the problem of repositioning single ﬁbers and
the diﬃculties associated with treatment-induced imaging
artifacts.Invitrostudieshaveshownthatsimultaneoustreat-
ment with four ﬁbers at 2.0cm separation produces lesions
that are 11 times bigger than those produced with a single
ﬁber, creating a lesion cylinder 4.0cm in diameter and 3cm
in height [42]. Simultaneous multiﬁber treatment produces
lesions averaging 3.6 × 3.1 × 2.8cm in normal canine liver
[41].Bareﬁbersarenow being replacedmoreandmoreoften
by specially designed ﬁbers equipped with diﬀuser endings
that emit light up to a distance of 10–30mm and with liquid
cooling that increases lesion size by allowing higher power
whileavoidingcharring[43,44].Bysimultaneouslyinserting
four ﬁbers and using ﬁber cooling, tumors with a diameter
of 5.0cm can be safely eradicated in a single treatment ses-
sion, as reported in the largest series of local ablation in a
single institution [45]. Recently, using a 980nm diode laser
ablation system in an in vivo tumor model with an internally
cooled applicator, large ellipsoid thermal ablation with sharp
boundaries was obtained in less than 3 minutes [36].
Local tissue properties, in particular perfusion, have a
signiﬁcant impact on the size of ablative zone. Highly per-
fused tissue and large vessels act as a heat sink, as laser light
is absorbed by erythrocytic heme and transported from the
local area [46]. This phenomenon makes native liver paren-
chyma relatively more resistant to LA than tumor tissue and
is the basis for the use of hepatic inﬂow occlusion techniques
inconjunctionwithlasertherapysuchaslocalarterialembo-
lization [47–51].
One advantage of using laser technology is that there are
sophisticated systems for controlling ablative lesion charac-
teristics and size using feedback systems, and dose-planning
systems are available with laser technology [39, 42, 52–54].
Animportantpracticaladvantageoverotherthermalsources
is that the thin and ﬂexible laser ﬁbers make it possible to
r e a c ht u m o r sm o r ee a s i l ya n ds a f e l y[ 55].
Lightisdeliveredviaﬂexiblequartzﬁberswithadiameter
from 300 to 600μm. Conventional bare tip ﬁbers provideRadiology Research and Practice 3
a near spherical lesion about 15mm diameter at their ends
but have been largely replaced by interstitial ﬁbers, which
have ﬂat or cylindrical diﬀusing tips and are 10–40mm long,
providing a much large ablative area of up to 50mm [56, 57].
The use of beam splitting devices allows for the use of up
to four ﬁbers at once with corresponding increase in ablative
volume: multiple ﬁbers must be placed, however, and the
devices only work eﬀectively at lower powers [55]. By in-
creasing laser power, light transmission improves and the
ablative zones increase in size. However, increasing laser
power also causes local temperature to rise, leading to the
risk of overheating and carbonization of adjacent tissue. The
use of water-cooled laser application sheaths allows a higher
laser power output (up to 50W compared with 5W) while
preventing carbonization [58]. Thus, the use of multiple
water-cooled higher-power ﬁbers allows ablative zones of up
to 80mm diameter [44]. Water-cooled sheaths do require
wider-bore cannulas but are commonly placed via a coaxial
dilatation system from an 18G puncture. Recently, a novel
ablationlasersystemconsistingofa15W,980nmdiodelaser,
ﬂexible diﬀusing-tipped ﬁber optic, and 17-gauge internally
cooledcatheterwasintroducedinclinicalpractice;itachieves
a large well-circumscribed ellipsoid ablation zone up to
42mmingreatestdiameter(withthelasersoperatingat15W
for 120 seconds and two applicators) with sharp boundaries
between thermally ablated tumor in the center surrounded
by viable tumor tissue [36].
2.3. Real-Time Monitoring and Treatment Planning. Of the
range of imaging modalities available to guide percutaneous
laser ablation, the choice is based largely on local experience
and resource availability. Local tumor destruction with heat
is based on the assumption that the whole tumor can be
selectively destroyed by raising tumor temperature to a cri-
tical level for a deﬁnite period of time. This can be ensured
by a method that gives good thermal resolution of the rele-
vant tissue or, preferably, accurate real-time monitoring of
irreversible tissue damage. Non-invasive techniques are ideal
for clinical thermometry, but none yet fulﬁlls the require-
ments of routine clinical use.
Ultrasound- (US-) guided needle placement has the ad-
v a n t a g et h a ti ti sq u i c k ,p o r t a b l e ,a n dw i d e l ya v a i l a b l e ;i ti s
familiaralsotothoseusedtoperformingUS-guidedbiopsies.
The main disadvantage is that it oﬀers little reliable indica-
tion of the temperature or actual extent of the ablative zone
being created. In addition, US is not well suited because of
treatment-induced artifacts [48, 59, 60]. CT is not useful for
real-time monitoring because thermal tissue changes are not
visible within 24 hours [61].
In contrast, magnetic-resonance- (MR-) guided LA,
often in conjunction with liver speciﬁc contrast agent, oﬀers
real-time thermal mapping that allows the operator to visu-
alize the size, location, and temperature of the ablation zone
[58,62].Thistechniquetendstobeusedincombinationwith
the higher-power water-cooled laser systems as the increased
energy can be delivered in a safe and controlled manner
[63,64].However,MR-guidedLAislimitedbymachineavai-
lability and the procedural complexity with an overall proce-
dure time between 60 and 120 minutes [45, 65]. This may
explain why laser ablation is not widely used compared with
RF ablation. Newly developed MR-compatible applicators
allow performance of the whole procedure in the MR suite,
which may reduce procedure time and improve technical ef-
fectiveness. This is under investigation in clinical trials [66].
US-guided laser systems, instead, tend to use multiple
lower-power ﬁber with a lower total energy delivery resulting
in truly quick procedure time [55, 67]. It is possible to
achieve a mean ablation zone diameter of 3.0cm with this
technique with a single illumination of 6 minutes [55].
ThermalimagingcanbeperformedonmostMRsystems,
with thermal changes being easier to demonstrate as magnet
ﬁeld strength increases. There are several methods of mea-
suring tissue temperature changes with MR. The simplest,
and most widely used technique, is measuring modiﬁcations
in T1 value of tissues which decreases in linear relationships
with increasing tissue temperature up to approximately 55◦C
[68]. Techniques that measure changes in the tissue diﬀusion
a r em o r ea c c u r a t e ,u pt o±1◦C, but require long acquisition
times and, therefore, suﬀer from patient motion artifacts
[69]. Another technique measures changes in the proton
resonance frequency shift (phase shift). Again, this measures
temperature changes very accurately but is not suitable for
use in fatty tissue and is less suited to open MR units as
it requires a homogeneous magnetic ﬁeld [70]. All of these
techniques are best used in combination with subtraction
techniques, that is, pretreatment image subtraction from
heating image, which allows very accurate assessment of
lesion size, but is sensitive to motion and misregistration
artifacts [71].
In addition to thermometry, the use of “open” magnets
with the inherent lower ﬁeld and gradient strengths allows
real-timeimagingofneedleplacementinamultiplanarman-
ner, at variance with CT and is not limited by the presence of
bone or gas, unlike US. The drawbacks of open magnets are
the lower image quality and the increased scan time.
In contrast, conventional closed magnets require ﬁber
placement using CT or US with subsequent transfer into MR
scanner for thermal mapping. This has the disadvantage of
requiring patient transfer mid procedure although it does
provide faster imaging and thermal mapping than an open
system [43, 67]. The use of MR guidance and thermometry
is currently only feasible with LA systems, as it uses a comp-
letely metal free system and does not produce any radiofre-
quency interference [68, 69]. Most RF systems are currently
not suitable for MR usage, both because of steel within the
electrodes and the degradation of image quality by extrane-
ous RF noise produced by the RF generators. Although MR-
compatible systems have been developed in practice, the RF
noise remains problematic [72].
Considering the diﬃculties in real-time imaging, it is
important that methods based on the production of heat en-
sure reproducible and cytotoxic temperatures in the periph-
ery of tumor tissue. One way to ensure this is to use feedback
control of the treatment eﬀect, for example, to let measured
temperatures control the energy output in order to achieve
a constant temperature level and reproducible lesion size
[39, 52]. Another way to control lesion size is to use a dose-
planningsystem.ThishasbeendevelopedforLAandenables4 Radiology Research and Practice
lesion size to be calculated for diﬀerent tissues, output pow-
ers, and treatment duration [42, 73].
2.4. Patients. Selection criteria vary from unit to unit depen-
dingonthetechniqueusedandthefacilitiesavailable[55,74]
but are broadly similar to those for other local ablative tech-
niques and are based on size, number and site of HCC in
patients who are deemed unsuitable for surgical resection or
transplant. The ideal lesions are those of ≤3cm in diameter,
single or one to three nodules each ≤3cm in diameter, ir-
respectiveoftheirlocation.Lesions adjacenttomajorvessels,
biliary ducts, bowel, or diaphragm can be treated with
caution even with MR-guided technique, but they are more
safely approached with ﬁne needle technique [55]. MR-
guided technique allows conﬁdent ablation of anatomically
moreproblematiclesionswiththeuseofreal-timethermom-
etry and multiplanar MR targeting [74]. Severe liver disease
(Child C) and coagulopathy are relative contraindication to
be evaluated in each individual patient, and extrahepatic
disease is generally considered an absolute contraindication.
LA has also been proven safe and eﬀective for the treatment
of cirrhotic patients awaiting liver transplant surgery [75].
Large lesions ≥5cm can be considered for laser ablation,
particularly if using a high-power system, though they can
require more than one treatment or/and pullback technique
with ﬁne needle method.
2.5. Outcome. LA has been performed mainly via the percu-
taneous route. The various laser ﬁber systems with their dif-
feringenergydeliverylevelsmakeitdiﬃculttocomparetheir
eﬀectiveness and complication rates. In addition, the ranges
of imaging modalities used at follow-up, combined with a
variety of deﬁnitions of treatment success, make comparison
of data diﬃcult. Primary eﬀectiveness relates to complete
lesion ablation as assessed by either CT or MR at a deﬁned
point after procedure and after a deﬁned number of treat-
ments.Dataregardinglong-termsurvivalratesforLAinpart
reﬂect the novelty of the treatment and the rapid advances
in technology, particularly in relation to the laser ﬁbers.
LA has been proven safe and feasible for the treatment of
HCCs in multiple cohort studies [45, 55, 63, 64, 67, 74, 76–
79]. The results are summarized in Table 1. According to
the multicenter study involving 432 cirrhotic patients (single
tumor ≤4cm or three nodules ≤3cm each) with 548 lesions,
the ideal candidates for LA are younger (<73 years) patients
with normal serum albumin levels and tumor size ≤2cm
who are highly likely to achieve complete tumor ablation
[79]. In this study, patients with Child-Turcotte-Pugh class
Aw i t ht u m o rs i z e≤3cm and a well-diﬀerentiated histologic
pattern who achieved an initial complete ablation had a
median survival time of 65 months (95% CL, 38 to 92
months), and those with a main tumor size ≤2cm and
sustained necrosis to initial complete response had a median
survival time of 63 months (95% CL, 48 to 78 months),
which further increased to 68 months (95% CL, 22 to 114
months) in those with a well-diﬀerentiated histology. The
median time to recurrence was 24 months (95% CL, 20 to
28 months), and the median disease-free survival time was
26 months (95% CL, 22 to 30 months) [79]. Results reported
by those groups using water-cooled higher-power MR-
guided laser ablation have been promising. Eichler et al. [74]
reported mean survival rates of 4.4 years (95% CL, 3.6–5.2)
in a series of 39 patients with 61 HCCs with complete ab-
lation rate of 98%.
LargelesionscanbesuccessfullytreatedbycombiningLA
with transarterial chemoembolization (TACE). This modal-
ity is a safe and eﬀective palliative treatment for large HCC.
In the treatment of 30 large lesions (3.5–9.6cm) using LA
followed by TACE, it was possible to achieve 90% ablation
rate with survival rates of 92%, 68%, and 40% at 1, 2, and
3 years without signiﬁcant complications [80]. Ferrari et al.
[81] supported this suggestion, demonstrating improved ab-
lation rates and survival in patients with HCC >5cmgiven
combination treatment over LA alone.
2.6. Complications. Reported complication rates for laser ab-
lation compare favorably to those of surgery. Arienti et al.
[82] reported complication rates for 520 patients with 647
HCCs treated with 1064 laser sessions considering 90 factors
for each record, including tumor characteristics. They report
0.8% deaths and 1.5% major complication rate. An earlier
report by Vogl et al. [45] included 899 patients, of whom 42
had HCC, with 2520 lesions treated with 2132 laser sessions
under CT/MR guidance, with 0.1% mortality and 1.8%
majorcomplicationrate.Bothgroupsreportedcommonside
eﬀects of asymptomatic pleural eﬀusion (7.3% and 6.9%),
postprocedural fever (33.3% and 12.3%), and severe pain
(7.5% and 11.5%). Neither of the above groups reported
tumor seeding. As a rule, tumor seeding has rarely been re-
ported after laser ablation.
2.7. Comparison with Other Hyperthermic Ablative Tech-
niques. In their randomized controlled prospective (RCT)
study, Ferrari et al. [83] treated 81 cirrhotic patients with 95
biopsy proven ≤4cm HCCs comparing LA with RF ablation.
Two matched groups were randomized to US-guided RF or
LA under general anesthesia. The authors adopted multiple
ﬁber technique using 5W per ﬁber delivering a maximum of
1800J per ﬁber per single illumination [55]. Assessment of
response was evaluated by dynamic CT scan. They reported
no signiﬁcant diﬀerence overall in survival rates between the
two methods, with cumulative rates of 91.8%, 59.0%, and
28.4% at 1, 3, and 5 years, respectively. However, they de-
monstrated a statistically signiﬁcant higher survival rate for
RF over LA for Child A patients (P = 0.9966) and nodules
≤2.5cm (P = 0.01181). They reported no signiﬁcant com-
plications. This work added to the same groups’ previous
published improved survival rates in patients treated with
LA, compared to those treated with either TACE or percu-
taneous ethanol injection (PEI) [84]. To date, Di Costanzo
et al. (unpublished data) treated in an ongoing RCT (esti-
mated sample, 140 patients) 95 patients with 109 biopsy
proven HCCs (single tumor ≤5cm or three nodules ≤3cm
each) with RF and LA (45 and 52, resp.). The two groups
were comparable for median age (71 years), male/female
(33/12-RF, 34/16-LA) Child-Turcotte-Pugh A/B (40/5-RF,
46/4-LA), and median diameter of HCC nodules (2.5cm-RF,
3.0cm-LA). With a median follow-up of 9 months (range,Radiology Research and Practice 5
Table 1: Studies reporting the outcome of Laser Ablation for small hepatocellular carcinoma.
Authors Number of
tumors/patients
Size of tumors
(cm)
mean (SD)
Local
recurrence
rate (%)
Complete
ablation∗
(%)
Overall survival (%)
Major com-
plications
rate∗∗ (%)
Mortality
rate (%)
3-year 5-year
Giorgio et al. [76] 85/77 3.2 (1.0–6.6) 18 82.5+ 3.7+ 1.2+
Pacella et al. [80]
30/30 5.2 ± 0.0
(3.5–9.0) 7 90.0+ TACE 60.0§ 00
15/30 1.9 ± 3.5
(0.8–3.0) 0 100.0 0 0
Pacella et al. [67] 92/74 2.4 ± 0.7
(0.8–4.0) 6 97.0 73.0§ 31.0§ 00
Eichler et al. [74] 39/61 >2.0 0 97.5 Mean 4.4
years 00
Dick et al. [64] 19/19 50.7# Mean 14.6
months#
Pacella et al. [77] 169/148 2.6 ± 0.8 15 82.0 58.0§ 30.0§ 0.5 0.6
Pacella et al. [79] 548/432
(multicenric study) 2.4 ± 0.8 20 79.6 41.0§ 1.6 0.2
+Calculated in mix histologic tumor types (seventy-seven patients had hepatocellular carcinoma (HCC)). Twenty-seven had metastases from colocarcinoma
(n = 25) or lung (n = 2).
∗Calculated per tumor.
∗∗Calculated per patient.
§Calculated in patients with Child-Turcotte-Pugh class A.
#Calculated in mix histologic tumor types (nineteen patients had 19 HCCs, eleven patients had metastases from a variety of primary tumors, and ﬁve patients
had metastatic carcinoid).
1–25months),completetumorablation(CTA)wasobserved
in 95.5% and 96.0% of cases in RF and LA, respectively.
Overall, HCC recurrence occurred in 24 (15 RF and 9 LA)
patients. Local recurrences were 9 in RF group and 3 in LA
group. Median time tumor recurrence (TTR) was 15 (95%
CL, 10–20) and 19 (95% CL, 17–23) months in RF and LA
groups, respectively, (P = 0.051). One-year progression-free
survival rate was 55% in RF group and 74% in LA group.
One-year survival probability was 92% and 95% in RF and
LA groups, respectively. Neither major complications nor
signiﬁcant treatment-related morbidity was registered in
either groups. Di Costanzo et al. concluded that LA was as
eﬀective as RF in inducing the complete response of HCC
nodules. A longer TTR and a lower recurrence rate were ob-
served in LA group. These interesting data have to be evalu-
atedandconﬁrmedattheendofthefollow-upanticipated in
June 2013.
3. Conclusion
LA of HCC has proven itself to be a safe and eﬀective local
therapy for patients with HCC nodules for whom surgical
resectionisnotpossible.Nevertheless,furtherdatafromran-
domized trials are required to establish long-term survival
rates for higher-power water-cooled systems before this kind
of treatment can be fully validated as a standard treatment.
It appears that RF, LA, or MW should replace PEI and cryo-
therapy, and, to date, there is little diﬀerence in outcome bet-
ween RF and LA using the latest technological developments
[21, 85].
Thus far, local ablation of hepatic disease has been used
for unresectable tumors, but these hyperthermic therapies
might be considered as a ﬁrst-line therapeutic option in the
subgroup of patients with HCC nodules ≤2cm in diameter
[86, 87] and, in our opinion, particularly in cases with well-
diﬀerentiated histologic pattern [79]. In the future, with the
reﬁnements of the technology and increased experience with
these techniques, it will be possible to safely and completely
destroy HCC ≥5cm as well, even in patients suitable for sur-
gery. The advantage of local tumor destruction include (a)
selective damage with a smaller immunosuppression and a
smaller release of growth factors [21, 88], (b) minimal treat-
ment morbidity and mortality, and (c) the possibility of star-
ting chemotherapy before or at the time of local therapy
[89,90].Themainproblemswithinsituablationarethelack
of good imaging techniques to determine the actual extent of
disease at intra- and extrahepatic sites and the lack of real-
time monitoring of treatment precision and irreversible tis-
sue eﬀect. The percutaneous approach needs to be developed
and has not yet been proven to give complete tumor ablation
rates that permit its use outside controlled clinical studies. It
might be valuable in a few truly unresectable or inoperable
patients or in selected patients. In the vast majority of cases,
it should still be used and evaluated only in prospective ran-
domized studies.
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